|
James W. Larrick, M.D. Ph.D. has an international reputation in biotechnology [cytokines, therapeutic antibodies, molecular biology, pharmaceutical drug development] having written or co-authored eight books, over 220 papers/chapters and fifteen patents. He serves on the editorial board of six journals. Dr. Larrick has worked on various aspects of therapeutic antibodies and other protein therapeutics for the past 20 years.
Dr. Larrick received his M.D. and Ph.D. degrees from Duke University School of Medicine, Durham, NC. After housestaff training in the Department of Medicine at Stanford University School of Medicine, he completed a post-doctoral fellowship in the Stanford Cancer Biology Research Labs with Professor Henry S. Kaplan. In 1982, he joined Cetus Immune Research Labs, Palo Alto, CA, where he became Director of Research in 1986. While at Cetus he pioneered the use of PCR for the construction of recombinant antibodies. In 1988 he moved to Genelabs Inc., Redwood City, CA, as Director of Exploratory Research. In 1991, Dr. Larrick founded the Palo Alto Institute of Molecular Medicine, a non-profit research institute situated near Stanford University. Since then he has founded more than a dozen biopharmaceutical companies: Panorama Research Inc., Planet Biotechnology Inc., Kalobios, Nugen Technologies, Medlogic, Panolife Products, PanResearch, Neuromolecular, Absalus, and Quality Clinical Labs, are based in California; PanGenetics B.V. (merged with Tanox Inc.) and TargetQuest B.V. (merged with Dyax Inc.) are headquartered in The Netherlands. Currently he serves on the Boards of five early stage companies and continues to pursue entrepreneurial activities through TENEX Medical Investors in Silicon Valley and 7X, an investment fund he co-founded in The Netherlands. | 